PHR1851
奥美沙坦酯
Pharmaceutical Secondary Standard; Certified Reference Material
别名:
Olmesartan medoxomil
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C29H30N6O6
化学文摘社编号:
分子量:
558.59
UNSPSC Code:
41116107
NACRES:
NA.24
MDL number:
InChI
1S/C29H30N6O6/c1-5-8-23-30-25(29(3,4)38)24(27(36)39-16-22-17(2)40-28(37)41-22)35(23)15-18-11-13-19(14-12-18)20-9-6-7-10-21(20)26-31-33-34-32-26/h6-7,9-14,38H,5,8,15-16H2,1-4H3,(H,31,32,33,34)
SMILES string
CCCC1=NC(C(O)(C)C)=C(C(OCC2=C(C)OC(O2)=O)=O)N1CC(C=C3)=CC=C3C4=CC=CC=C4C5=NN=NN5
InChI key
UQGKUQLKSCSZGY-UHFFFAOYSA-N
grade
certified reference material, pharmaceutical secondary standard
agency
traceable to Ph. Eur. Y0001405, traceable to USP 1478367
API family
olmesartan
CofA
current certificate can be downloaded
packaging
pkg of 200 mg
application(s)
pharmaceutical
format
neat
storage temp.
-10 to -25°C
Quality Level
Gene Information
human ... AGTR1(185)
正在寻找类似产品? 访问 产品对比指南
General description
This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.
Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
Olmesartan Medoxomil is an AT1 subtype angiotensin-II receptor antagonist used in the management of hypertension. It prevents angiotensin II from binding to the AT1 receptors, thereby decreasing vasoconstriction.
Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
Olmesartan Medoxomil is an AT1 subtype angiotensin-II receptor antagonist used in the management of hypertension. It prevents angiotensin II from binding to the AT1 receptors, thereby decreasing vasoconstriction.
Application
Theis pharmaceutical secondary standard can also be used as follows:
- Development and validation of an isocratic ultra-high performance liquid chromatography (UHPLC) based stability indicating method to determine olmesartan medoxomil and amlodipine besylate in combined tablet dosage forms
- Simultaneous determination of Olmesartan medoxomil and chlorthalidone by reversed phase-high performance liquid chromatography (RP-HPLC) in tablets
- Quantification of olmesartan medoxomil and its degradation products in bulk drugs and pharmaceutical formulations by using a systematic quality by design (QbD)-based reverse-phase liquid chromatography method
- Reversed phase-high performance liquid chromatographic (RP-HPLC) analysis of olmesartan medoxomil and hydrochlorothiazide in their combined tablet dosage form
- Determination of olmesartan medoxomil and amlodipine besylate in their combined tablet dosage form by absorption subtraction method, ratio subtraction with extended ratio subtraction method, dual wavelength technique, and second order derivative spectrophotometry
Analysis Note
These secondary standards offer multi-traceability to the USP and EP primary standards, where they are available.
Other Notes
To see an example of a Certificate of Analysis for this material enter LRAC2529 in the Documents slot below. This is an example certificate only and may not be the lot that you receive.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
DAD based stability indicating RP-UPLC method for simultaneous determination of olmesartan medoxomil and amlodipine besylate
Kerai JR, et al.
Pharmaceutical Chemistry Journal, 52, 959-964 (2019)
Development and validation of RP-HPLC method for simultaneous determination of a combined formulation of olmesartan medoxomil & hydrochlorothiazide
Sony A, et al.
World Journal of Pharmacy and Pharmaceutical Sciences, 9, 1468-1488 (2020)
Development and validation of RP-HPLC method for the simulteneous estimation of olmesartan medoxomil and chlorthalidone in tablet dosage form
Sawale V, et al.
International Journal of Pharmacy and Pharmaceutical Sciences, 7, 266-269 (2015)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持